Tag: HIV

The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS).

Gilead localizes the production of hepatitis C and HIV drugs in Russia

According to the agreement Pharmstandard production facilities will manufacture Sovaldi® for the treatment of chronic hepatitis C and Truvada® for the treatment of HIV.

First Chinese HIV drug is approved for human clinical trials in USA

clinical trials
Chinese first domestically-made anti-HIV drug has been given approval by the US Food and Drug Administration (FDA) to begin the next phase of clinical trials in America.

Viriom intends to produce Elpida at the facilities of Pharmstandard

JSC Pharmstandard, a Russian pharmaceutical industry leader, and Viriom LLC, a company engaged in the development of innovative medicines, signed an agreement on intentions.

Yale scientists contrived a promising HIV therapy

In a study, a new HIV drug reduced viral replication and increased immune cells in individuals with advanced, drug-resistant HIV infection.

ViiV Healthcare unveiled positive results from trial of two-drug HIV regimen

viiv healthcare
ViiV Healthcare announced positive headline results from its global, phase III ATLAS study of a long-acting, injectable two-drug regimen (2DR) for the treatment of HIV.

Gilead’s HIV treatment obtained EU marketing authorization

Gilead Sciences announced that the European Commission has granted Marketing Authorization for Biktarvy®, a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection.

Gilead and Hookipa Biotech will develop HIV and Hepatitis B treatments

gilead sciences
Hookipa Biotech AG, an Austrian clinical-stage biotech company, and Gilead Sciences, a research-based biopharmaceutical company, entered into a research collaboration and license agreement.

ViiV Healthcare’s HIV treatment showed positive results in phase III studies

viiv healthcare
The GEMINI studies are part of innovative clinical trial programme for two-drug regimens that seeks to address long-term toxicity concerns of people living with HIV by reducing the number of medicines used in their treatment.

China Food and Drug Administration approved a new HIV drug

China Food and Drug Administration (FDA) has approved the sale of a new drug for the treatment of HIV-1 infection, the maker of the drug said.

Manufacturing of Tivicay® in Moscow will be launched no later than May 2019

GSK and Servier signed an agreement to launch the manufacturing of innovative HIV drug Tivicay® (INN: dolutegravir) in the production facility of Servier Rus pharmaceutical plant in Moscow.

India, Sweden and The Netherlands will collaborate on HIV research programme

The Governments of India and The Netherlands on Wednesday will announce the launch of the first-of-its-kind collaborative research programme on HIV/AIDS, between India, The Netherlands and Sweden.

ViiV Healthcare received EU marketing authorisation for its HIV treatment

viiv healthcare
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, announced that the European Commission has granted marketing authorisation for Juluca.

Russian drug for HIV treatment is getting close to clinical trials

The Central Research Institute of Epidemiology of Rospotrebnadzor is working to create fundamentally new medicinal products for gene therapy, genetic prevention and molecular vaccination against HIV infection.

ViiV Healthcare received positive opinion for Juluca in Europe

viiv healthcare
ViiV Healthcare, the global specialist HIV company, announced that the CHMP has issued a Positive Opinion recommending marketing authorisation for Juluca for the treatment of HIV infection.

ChemRar has started the production of HIV drug

ChemRar, a Russian company based in the business incubator of the city of Khimki, began to produce a drug for HIV‐infected patients. This is not a cure for AIDS, but a so-called “preventive drug”.

Share of Russian HIV and cancer drugs increased significantly

The share of Russian-made medicines in the List of Vital and Essential Drugs increased by 10% in monetary terms over the five past years. This was announced by the Deputy Minister of Industry and Trade of the Russian Federation.